From the Department of Nuclear Medicine, University of Health Sciences, Gazi Yaşargil Training and Research Hospital.
Department of Pathology, Dicle University Medical School, Diyarbakir, Turkey.
Clin Nucl Med. 2021 Aug 1;46(8):e433-e435. doi: 10.1097/RLU.0000000000003594.
68Ga-fibroblast activation protein-specific inhibitor (FAPI)-04 PET/CT was performed in a patient with left lower outer quadrant breast cancer who had 18F-FDG PET/CT imaging. 68Ga-FAPI-04 PET/CT showed higher accumulation of radiotracer in primary tumor and axillary lymph nodes than 18F-FDG PET/CT. In addition, focal increased FAPI uptake was observed in another nodular lesion in the lower inner quadrant in the same breast, which was considered malignant. However, Tru-Cut biopsy of this lesion was reported as benign lymphoid tissue. This case showed that all FAPI accumulation in breast tissue should not be interpreted in favor of malignancy; histopathological confirmation is required.
68Ga-成纤维细胞激活蛋白特异性抑制剂（FAPI）-04 PET/CT 是在一位左外下象限乳腺癌患者中进行的，该患者曾进行过 18F-FDG PET/CT 成像。68Ga-FAPI-04 PET/CT 显示放射性示踪剂在原发肿瘤和腋窝淋巴结中的积聚高于 18F-FDG PET/CT。此外，在同一乳房的下内象限的另一个结节性病变中观察到 FAPI 摄取的局部增加，这被认为是恶性的。然而，该病变的 tru-cut 活检报告为良性淋巴组织。该病例表明，不应该根据所有乳腺组织中的 FAPI 积聚来支持恶性肿瘤的诊断；需要进行组织病理学确认。
